BioNTech
BNTX
95.25
-0.48
-0.50%
BioNTech
US · BNTX
#801 by market cap
Listed 2019
95.25
-0.48
-0.50%
Live - 5344 symbols - heartbeat 418s ago
· 2026-10-08 07:37
Pre-market
94.26
-1.04%
After-hours
96.00
+0.79%
Overnight
95.00
-0.26%
- Market cap
- 23.93B
- P/E (TTM)i
- -12.68
- P/Bi
- 1.20
- EPSi
- -5.26
- Div yieldi
- 0.00%
- 52W posi
- 35%
Reader sentiment
Are you bullish or bearish on BNTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.14, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +4.32% YoY
Margins
- Gross margin
- 77.64%
- Operating margin
- -22.32%
- Net margin
- -39.59%
Key ratios & quality
- Enterprise valuei
- 9.32B
- Altman Z-Scorei
- 7.14
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 127.58M | 108.60M | 482.30M | 18.98B | 17.31B | 3.82B | 2.75B | 2.87B |
| Gross profit | 113.89M | 91.20M | 423.00M | 16.07B | 14.32B | 3.22B | 2.21B | 2.23B |
| Selling & admin expenses | 27.07M | 43.30M | 108.50M | 327.20M | 541.20M | 587.10M | 712.70M | 698.20M |
| Research & development | 143.07M | 226.50M | 645.00M | 949.20M | 1.54B | 1.78B | 2.25B | 2.10B |
| Operating profit | -53.90M | -181.50M | -82.40M | 14.93B | 12.30B | 875.60M | -709.40M | -640.70M |
| Pretax profit | -47.66M | -179.40M | -145.80M | 15.05B | 12.95B | 1.19B | -677.70M | -1.05B |
| Tax | 600.00K | -200.00K | -161.00M | 4.75B | 3.52B | 255.80M | -12.40M | 85.30M |
| Net profit | -48.26M | -179.20M | 15.20M | 10.29B | 9.43B | 930.30M | -665.30M | -1.14B |
| Basic EPS | 0 | -1 | 0 | 42 | 39 | 4 | -3 | -5 |
| Diluted EPS | -0.21 | -0.85 | 0.06 | 39.63 | 37.77 | 3.83 | -2.77 | -4.70 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 182.80M | 260.80M | 1.52B | 907.40M | 118.10M | 105.60M |
| Gross profit | 99.00M | 184.40M | 1.37B | 574.10M | 46.70M | 8.60M |
| Selling & admin expenses | 120.60M | 137.40M | 148.50M | 291.70M | 163.80M | 197.80M |
| Research & development | 525.60M | 509.10M | 564.80M | 505.40M | 557.00M | 551.00M |
| Operating profit | -534.10M | -472.00M | 653.90M | -280.50M | -671.20M | -938.70M |
| Pretax profit | -445.40M | -402.70M | 24.70M | -227.40M | -568.10M | -858.70M |
| Tax | -29.60M | -16.10M | 53.40M | 77.60M | -36.20M | -37.90M |
| Net profit | -415.80M | -386.60M | -28.70M | -305.00M | -531.90M | -820.80M |
| Basic EPS | -2 | -2 | 0 | -1 | -2 | -3 |
| Diluted EPS | -1.73 | -1.60 | -0.12 | -1.25 | -2.10 | -3.24 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 448.96M | 560.15M | 1.67B | 15.07B | 21.92B | 19.53B | 18.80B | 16.15B |
| Cash & ST investments | 411.83M | 520.83M | 1.35B | 2.07B | 14.06B | 16.55B | 16.78B | 14.88B |
| Inventory | 5.79M | 11.72M | 64.10M | 502.50M | 439.60M | 357.70M | 283.30M | 110.70M |
| Total assets | 652.99M | 797.65M | 2.32B | 15.83B | 23.28B | 23.01B | 22.53B | 21.99B |
| Total current liabilities | 126.12M | 138.14M | 606.00M | 3.48B | 2.95B | 2.07B | 2.52B | 2.14B |
| Short-term debt | -- | 5.31M | 9.10M | 129.90M | 36.00M | 28.10M | 39.50M | 52.20M |
| Long-term debt | -- | 68.90M | 231.00M | 171.60M | 176.20M | 191.00M | 214.70M | 215.20M |
| Total liabilities | 385,986,000.00 | 304,155,000.00 | 946,800,000.00 | 3,937,100,000.00 | 3,223,500,000.00 | 2,760,400,000.00 | 3,118,600,000.00 | 2,764,400,000.00 |
| Total equity | 267.00M | 493.49M | 1.37B | 11.89B | 20.06B | 20.25B | 19.41B | 19.22B |
| Retained earnings | -245.77M | -424.83M | -409.60M | 9.88B | 18.83B | 19.76B | 19.10B | 17.96B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 15.63B | 15.93B | 15.83B | 16.15B | 15.53B | 15.30B |
| Cash & ST investments | 14.11B | 14.04B | 14.52B | 14.88B | 14.64B | 14.78B |
| Inventory | 254.40M | 230.70M | 225.70M | 110.70M | 103.80M | 100.60M |
| Total assets | 21.18B | 21.64B | 21.34B | 21.99B | 21.07B | 20.34B |
| Total current liabilities | 1.53B | 1.85B | 2.22B | 2.14B | 1.77B | 1.95B |
| Short-term debt | 55.50M | 52.40M | 53.40M | 52.20M | 56.70M | 57.20M |
| Long-term debt | 237.50M | 217.20M | 192.00M | 215.20M | 66.60M | 258.90M |
| Total liabilities | 2,255,800,000.00 | 3,132,500,000.00 | 2,863,800,000.00 | 2,764,400,000.00 | 2,376,300,000.00 | 2,585,100,000.00 |
| Total equity | 18.93B | 18.51B | 18.48B | 19.22B | 18.70B | 17.76B |
| Retained earnings | 18.68B | 18.30B | 18.27B | 17.96B | 17.43B | 16.61B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -58.88M | -198.50M | -13.50M | 889.70M | 13.58B | 5.37B | 207.70M | 456.00M |
| Depreciation & amortization | 21.98M | 33.90M | 38.70M | 75.20M | 123.30M | 183.40M | 298.00M | 382.80M |
| Free cash flow | -126.03M | -269.60M | -98.90M | 735.70M | 13.21B | 4.67B | -244.60M | -293.00M |
| Dividends paid | -- | -- | 0 | 0 | -484.30M | -- | -- | -- |
| Stock buybacks / issuance | 361.73M | 375.40M | 753.00M | 160.90M | -875.90M | -738.50M | 0 | 0 |
| Ending cash balance | 411.50M | 519.10M | 1.21B | 1.69B | 13.88B | 11.66B | 9.76B | 7.68B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -780.70M | 146.50M | 780.70M | 309.50M | -421.00M | 10.50M |
| Depreciation & amortization | 42.80M | 51.00M | 124.20M | 164.80M | 121.30M | 266.10M |
| Free cash flow | -1.40B | 116.30M | 742.10M | 247.40M | -499.90M | -44.90M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | -- | -- | -- | -129.20M |
| Ending cash balance | 10.18B | 10.27B | 10.09B | 7.68B | 9.94B | 9.74B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -44.29 | -47.14 | 1.63 | 155.18 | 59.06 | 4.62 | -3.36 | -5.88 |
| ROA %i | -9.35 | -24.69 | 0.98 | 113.42 | 48.25 | 4.02 | -2.92 | -5.10 |
| ROIC %i | -29.10 | -40.18 | 1.53 | 149.14 | 58.20 | 4.57 | -3.25 | -5.75 |
| 5-year avg ROE %i | -- | -- | -- | -- | 24.89 | 34.67 | 43.43 | 41.92 |
| EBIT margin %i | -36.01 | -163.66 | -29.81 | 79.32 | 74.93 | 23.68 | -24.18 | -36.12 |
| FCF / sales %i | -- | -- | -- | 3.88 | 76.34 | 122.18 | -- | -- |
| Current ratioi | 3.56 | 4.05 | 2.75 | 4.33 | 7.43 | 9.43 | 7.45 | 7.54 |
| Quick ratioi | 3.49 | 3.92 | 2.50 | 4.15 | 7.19 | 9.12 | 7.26 | 7.40 |
| Debt / assetsi | 8.30 | 9.30 | 10.36 | 1.90 | 0.91 | 0.95 | 1.13 | 1.22 |
| LT debt / equityi | 20.37 | 13.96 | 16.84 | 1.44 | 0.88 | 0.94 | 1.11 | 1.12 |
| Interest coveragei | -26.69 | -103.45 | -71.79 | 2,787.37 | 800.64 | -- | -52.79 | -73.00 |
| Revenue CAGR (3Y) %i | -- | -- | 98.57 | 429.85 | 442.20 | 99.32 | -47.47 | -45.06 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | 294.09 | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.94 | -1.84 | -3.04 | -5.88 | -6.66 | -9.30 |
| ROA %i | -3.53 | -1.57 | -2.61 | -5.10 | -5.93 | -8.03 |
| ROIC %i | -3.68 | -1.75 | -3.00 | -5.75 | -6.60 | -9.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -27.29 | -13.05 | -6.74 | -36.12 | -42.39 | -60.95 |
| FCF / sales %i | -- | -- | -- | -- | 21.60 | 16.78 |
| Current ratioi | 10.18 | 8.61 | 7.12 | 7.54 | 8.80 | 7.85 |
| Quick ratioi | 9.86 | 8.37 | 6.89 | 7.40 | 8.64 | 7.71 |
| Debt / assetsi | 1.38 | 1.25 | 1.15 | 1.22 | 1.44 | 1.55 |
| LT debt / equityi | 1.25 | 1.17 | 1.04 | 1.12 | 1.32 | 1.46 |
| Interest coveragei | -17.93 | -30.06 | -- | -73.00 | 75.75 | -112.95 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 07:37:10 · For reference only, not investment advice and not tailored to your situation.